Diarrhea Due To E Coli — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for diarrhea due to e coli. 17 active patents protecting 1 drugs from 1+ originators. First major cliff: 2027. Daily refresh.

1
Approved drugs
17
Active US patents
66/100
Avg vulnerability
$1.5B
Annual revenue covered

Originators in Diarrhea Due To E Coli

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Bausch Health 17 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating diarrhea due to e coli. Each bar = one year. Y-axis scaled to peak year (15 patents).

2
27
15
29

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Xifaxan
rifaximin
 Bausch Health 17 66 $1.5B 2027-09-02

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11779571 Xifaxan method of use 83 2029-02-26
11564912 Xifaxan method of use 83 2029-02-26
8193196 Xifaxan method of use 80 2027-09-02
10765667 Xifaxan method of use 75 2029-02-26
10456384 Xifaxan method of use 75 2029-02-26
8829017 Xifaxan method of use 73 2029-07-24
7928115 Xifaxan method of use 73 2029-07-24
8642573 Xifaxan method of use 73 2029-10-02
8309569 Xifaxan method of use 68 2029-07-18
10314828 Xifaxan method of use 68 2029-07-24

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8193196 Xifaxan composition of matter 22 2027-09-02
8969398 Xifaxan method of use 68 2029-10-02
10709694 Xifaxan method of use 68 2029-07-24
10314828 Xifaxan method of use 68 2029-07-24
9421195 Xifaxan method of use 68 2029-07-24
8946252 Xifaxan method of use 68 2029-07-24
9629828 Xifaxan method of use 68 2029-07-24
10335397 Xifaxan method of use 68 2029-07-24
8309569 Xifaxan method of use 68 2029-07-18
8642573 Xifaxan method of use 73 2029-10-02

Related